| 000 | 01874 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515200722.0 | ||
| 264 | 0 | _c20100107 | |
| 008 | 201001s 0 0 eng d | ||
| 022 | _a1532-4192 | ||
| 024 | 7 |
_a10.3109/07357900802562996 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYildiz, Ramazan | |
| 245 | 0 | 0 |
_aBevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. _h[electronic resource] |
| 260 |
_bCancer investigation _cJan 2010 |
||
| 300 |
_a33-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aCamptothecin _xadministration & dosage |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aBuyukberber, Suleyman | |
| 700 | 1 | _aUner, Aytug | |
| 700 | 1 | _aYamac, Deniz | |
| 700 | 1 | _aCoskun, Ugur | |
| 700 | 1 | _aKaya, Ali Osman | |
| 700 | 1 | _aOzturk, Banu | |
| 700 | 1 | _aYaman, Emel | |
| 700 | 1 | _aBenekli, Mustafa | |
| 773 | 0 |
_tCancer investigation _gvol. 28 _gno. 1 _gp. 33-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/07357900802562996 _zAvailable from publisher's website |
| 999 |
_c19377768 _d19377768 |
||